BR0210549A - Antimaláricos de espiro e dispiro 1,2,4-trioxolano - Google Patents

Antimaláricos de espiro e dispiro 1,2,4-trioxolano

Info

Publication number
BR0210549A
BR0210549A BR0210549-7A BRPI0210549A BR0210549A BR 0210549 A BR0210549 A BR 0210549A BR PI0210549 A BRPI0210549 A BR PI0210549A BR 0210549 A BR0210549 A BR 0210549A
Authority
BR
Brazil
Prior art keywords
trioxolane
dispiro
spiro
group
spirocyclohexyl
Prior art date
Application number
BR0210549-7A
Other languages
English (en)
Inventor
Janathan L Vennerstrom
Jacques Chollet
Yuxiang Dong
Hugues Matile
Maniyan Padmanilayam
Yuanqing Tang
William N Charman
Original Assignee
Medicines Malaria Venture Mmv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicines Malaria Venture Mmv filed Critical Medicines Malaria Venture Mmv
Publication of BR0210549A publication Critical patent/BR0210549A/pt
Publication of BRPI0210549B1 publication Critical patent/BRPI0210549B1/pt
Publication of BRPI0210549B8 publication Critical patent/BRPI0210549B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C07D323/02—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"ANTIMALáRICOS DE ESPIRO E DISPIRO 1,2,4-TRIOXOLANO". São descritos um meio e método para tratamento de malária, esquistossomíase e câncer utilizando um espiro ou dispiro 1,2,4-trioxolano. Os 1,2,4-trioxolanos preferidos incluem um grupo de espiroadamantano em um lado do grupo de trioxolano e uma espirocicloexila no outro lado do grupo de trioxolano, pelo que o anel de espirocicloexila é de preferência substituído na posição-4. Em comparação com derivados semi-sintéticos de artemisinina, os compostos da presente invenção são estruturalmente simples, fáceis de sintetizar, não tóxicos e potentes contra parasitas maláricos.
BRPI0210549-7 2001-06-21 2002-06-21 antimaláricos de espiro e dispiro 1,2,4-trioxolano BRPI0210549B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/886.666 2001-06-21
US09/886,666 US6486199B1 (en) 2001-06-21 2001-06-21 Spiro and dispiro 1,2,4-trioxolane antimalarials
PCT/US2002/019767 WO2003000676A1 (en) 2001-06-21 2002-06-21 1,2,4-trioxolane antimalarials

Publications (3)

Publication Number Publication Date
BR0210549A true BR0210549A (pt) 2005-01-11
BRPI0210549B1 BRPI0210549B1 (pt) 2020-11-10
BRPI0210549B8 BRPI0210549B8 (pt) 2021-05-25

Family

ID=25389491

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210549-7 BRPI0210549B8 (pt) 2001-06-21 2002-06-21 antimaláricos de espiro e dispiro 1,2,4-trioxolano

Country Status (24)

Country Link
US (1) US6486199B1 (pt)
EP (1) EP1414813B1 (pt)
JP (1) JP4303585B2 (pt)
KR (1) KR100759144B1 (pt)
CN (1) CN1545508B (pt)
AT (1) ATE339411T1 (pt)
AU (1) AU2002327183B2 (pt)
BR (1) BRPI0210549B8 (pt)
CA (1) CA2451006C (pt)
CY (1) CY1106214T1 (pt)
DE (1) DE60214733T8 (pt)
DK (1) DK1414813T3 (pt)
ES (1) ES2271323T3 (pt)
HU (1) HUP0400246A3 (pt)
IL (1) IL159474A0 (pt)
MX (1) MXPA03011915A (pt)
NO (1) NO20035721L (pt)
PL (1) PL226418B1 (pt)
PT (1) PT1414813E (pt)
RU (1) RU2271357C2 (pt)
SI (1) SI1414813T1 (pt)
UA (1) UA78709C2 (pt)
WO (1) WO2003000676A1 (pt)
YU (1) YU100703A (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377002T3 (es) * 2002-06-06 2012-03-21 University Of Washington Conjugados covalentes entre los endoperóxidos relacionados con la artemisinina y las proteínas transportadoras de hierro y procedimientos de utilización
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
FR2862304A1 (fr) * 2003-11-14 2005-05-20 Centre Nat Rech Scient Molecules duales racemiques ou achirales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
US20080275112A1 (en) * 2004-07-23 2008-11-06 Schreiner Peter R Invention Concerning Aminoadamantane Compounds
US20060040761A1 (en) * 2004-08-23 2006-02-23 Sam-Kyu Shin Scale mark mat for putting practice
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
HUE033191T2 (en) * 2005-05-18 2017-11-28 Sun Pharmaceutical Ind Ltd Stable dosage forms of spiro and dispiro-1,2,4-trioxolane anti-malarial agents
WO2007036947A1 (en) * 2005-09-30 2007-04-05 Ipca Laboratories Limited Delayed release anti-malarial composition
CA2624750C (en) 2005-10-04 2012-01-03 The Director General, Defence Research And Development Organisation Anti-malarial compound isolated from gomphostemma niveum
WO2007112451A2 (en) * 2006-03-28 2007-10-04 University Of Washington Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
AU2007236115A1 (en) 2006-04-11 2007-10-18 Novartis Ag Organic compounds
WO2007132438A2 (en) * 2006-05-17 2007-11-22 Ranbaxy Laboratories Limited Antimalarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative
ES2400682T3 (es) * 2006-05-24 2013-04-11 Ranbaxy Laboratories Limited Procedimiento para la preparación de agentes anti-malaria de dispiro 1,2,4-trioxolano (sales de OZ277)
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
GB0619333D0 (en) * 2006-09-30 2006-11-08 Univ Liverpool Dispiro tetraoxane compounds
WO2008046109A2 (en) * 2006-10-13 2008-04-17 University Of Washington Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer
FR2924343A1 (fr) * 2007-12-04 2009-06-05 Palumed Sa Nouvelles utilisations therapeutiques de molecules duales contenant un derive peroxydique.
US20110172445A1 (en) * 2008-07-01 2011-07-14 National University Corporation Okayama University Novel Antischistosomal Agent
WO2010011684A2 (en) 2008-07-21 2010-01-28 The Regents Of The University Of California Prodrug and fluoregenic compositions and methods for using the same
CA2850089A1 (en) 2011-07-14 2013-01-17 Ranbaxy Laboratories Limited Stable dosage forms of arterolane and piperaquine
EP3104857A4 (en) 2014-02-14 2017-10-11 The Regents of The University of California Cyclic peroxides as prodrugs for selective delivery of agents
CN107207472B (zh) * 2014-12-23 2020-08-14 卑尔根生物股份公司 Akt激酶的抑制剂
RU2601315C1 (ru) * 2015-06-10 2016-11-10 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения пентаоксаспироалканов
US11072594B2 (en) 2017-06-27 2021-07-27 The Regents Of The University Of California Trioxolane agents
CN108424371B (zh) * 2018-01-19 2021-07-16 北京理工大学 2-(4-氨基环己基)-乙酸乙酯的制备方法
US20210386814A1 (en) * 2020-05-20 2021-12-16 Amanuel Tesfazion Methods and compound for the treatment of malaria

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621062A (en) 1966-10-25 1971-11-16 Sterling Drug Inc 2-(8-cyclohexyloctanoyl or 7-cyclohexylheptanoyl)-1-naphthol
US3673222A (en) 1969-11-26 1972-06-27 Sydney Archer 2-(8-cyclohexyloctyl or 7-cyclohexylheptyl)-1,4-naphthoquinone and process for preparation and use thereof
US3682991A (en) 1970-10-19 1972-08-08 Sterling Drug Inc 3,3,5-trimethylcyclohexyl-alkyl-carboxylic acids
US4916204A (en) 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US4816478A (en) 1987-08-24 1989-03-28 Thornfeldt Carl R Treatment of acquired immunodeficiency syndrome
US5053342A (en) 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
US5270344A (en) 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
JP2867529B2 (ja) 1990-01-22 1999-03-08 三菱電機株式会社 投写型表示装置
US5216175A (en) 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5219880A (en) 1991-03-29 1993-06-15 Dermatologic Research Corporation Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
US5510356A (en) 1991-10-03 1996-04-23 University Of Nebraska Board Of Regents Bisquinolines and processes for their production and use to treat malaria
US5171676A (en) 1991-10-31 1992-12-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of introducing hydroxyl groups into artemisinin and its derivatives
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
ATE152630T1 (de) 1992-07-28 1997-05-15 Procter & Gamble Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US5780675A (en) 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5578637A (en) 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5672624A (en) 1995-11-22 1997-09-30 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5817692A (en) 1995-11-22 1998-10-06 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5932591A (en) 1996-12-02 1999-08-03 Johns Hopkins University C3 substituted trioxanes useful as antiparasitic drugs

Also Published As

Publication number Publication date
AU2002327183C1 (en) 2003-01-08
RU2271357C2 (ru) 2006-03-10
ES2271323T3 (es) 2007-04-16
KR20040030697A (ko) 2004-04-09
CA2451006A1 (en) 2003-01-03
DE60214733T8 (de) 2008-02-21
JP2004535436A (ja) 2004-11-25
UA78709C2 (en) 2007-04-25
NO20035721D0 (no) 2003-12-19
SI1414813T1 (sl) 2006-12-31
BRPI0210549B8 (pt) 2021-05-25
CN1545508B (zh) 2012-06-06
WO2003000676A1 (en) 2003-01-03
NO20035721L (no) 2004-02-23
CA2451006C (en) 2011-08-23
YU100703A (sh) 2006-03-03
PT1414813E (pt) 2006-12-29
HUP0400246A3 (en) 2009-12-28
ATE339411T1 (de) 2006-10-15
RU2004101409A (ru) 2005-06-10
DK1414813T3 (da) 2007-01-02
CN1545508A (zh) 2004-11-10
DE60214733T2 (de) 2007-09-13
JP4303585B2 (ja) 2009-07-29
DE60214733D1 (de) 2006-10-26
PL226418B1 (pl) 2017-07-31
EP1414813B1 (en) 2006-09-13
CY1106214T1 (el) 2011-06-08
HUP0400246A2 (hu) 2004-08-30
US6486199B1 (en) 2002-11-26
KR100759144B1 (ko) 2007-09-14
MXPA03011915A (es) 2004-05-21
AU2002327183B2 (en) 2006-03-09
EP1414813A1 (en) 2004-05-06
BRPI0210549B1 (pt) 2020-11-10
PL367158A1 (en) 2005-02-21
IL159474A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
BR0210549A (pt) Antimaláricos de espiro e dispiro 1,2,4-trioxolano
CY1117133T1 (el) Ανθελονοσιακα δισπειρο-1,2,4-τριοξολανιων
BR0316883A (pt) Derivado de piridazin-3(2h)-ona, composto, processo para a preparação de um composto composição farmacêutica, uso do composto, método para o tratamento de um sujeito que está sofrendo de uma condição patológica ou doença susceptìvel de melhora por meio de inibição da fosfodiesterase 4 e produto de combinação
CY1107539T1 (el) Παραγωγα κουιναζολινης
WO2003018022A8 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
WO2009091433A3 (en) Spiro and dispiro 1,2,4-trioxolane antimalarials
CY1115148T1 (el) Ανθελονοσιακα δισπειρο 1,2,4-τριοξολανια
NO902301D0 (no) Fremgangsmaate for fremstilling av diarylstyrylkinolin-disyrer.
NO20033682L (no) Epothilone-derivater for behandling av refraktor-tumorer
ATE359786T1 (de) Camptothecin derivate
BR0209936A (pt) Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikk
DE69904282D1 (de) Verwendung von Chromane und/oder Chromene Derivaten zur Vermeidung von freien Radikalen induzierten oxidativen Reaktionen
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
DK1413305T3 (da) Aryl(eller heteroaryl)-azolylcarbinolderivater til behandling af urininkontinens
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
BR0208221A (pt) Combinação de uma taxano e uma cinase dependente de ciclina
WO2003070159A3 (en) Novel coumarin and chromene compounds and methods of treating or preventing viral infections
DK451884A (da) 2-(n-pyrrolidino)-3-isobutoxy-n-substituerede phenyl-n-benzyl-propylaminer, deres fremstilling og farmaceutiske anvendelse
NO20041542L (no) Fremgangsmate ved fremstilling av 14 beta-hydroksy-baccatin III-1,14-karbonat
Lin Stress Distribution in Budai Rukai
UY26522A1 (es) " derivados de aminometil-fenil- ciclohexano sustituidos, procedimiento para su preparación, su uso para la preparación de medicamentos y medicamentos que contienen estos compuestos".
FR2830092B1 (fr) Systeme pour la production de documents identifies par une numerotation sequentielle, et generateur de numerotation sequentielle

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2728 DE 18-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.